Drug Type Universal CAR-T |
Synonyms Anti-CD19 UCAR-T cell therapy (IASO Biotherapeutics), RD 301, RD301 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Preclinical | China | - | |
| Acute Lymphoblastic Leukemia | Preclinical | China | - | |
| Diffuse Large B-Cell Lymphoma | Preclinical | China | - | |
| Diffuse Large B-Cell Lymphoma | Preclinical | China | - |





